


-81-

What is claimed is:

1. A compound of the formula:



Formula I

wherein,

X represents $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{O}-$, $-\text{CH}_2\text{S}-$, or $-\text{CH}_2\text{NR}^{10}-$;

- 10 R^1 represents hydrogen, (C_1-C_4) alkyl, (C_3-C_7) cycloalkyl, hydroxy (C_1-C_4) alkyl, halo (C_1-C_4) alkyl, (C_1-C_4) alkyl-heterocycle, (C_1-C_4) alkyl-NH (C_1-C_4) alkylamine, or (C_1-C_4) alkyl-N,N- (C_1-C_4) dialkylamine;

R^2 represents hydrogen, halo, (C_1-C_4) alkyl, heterocycle, or substituted heterocycle;

- 15 R^3 represents hydrogen, halo, (C_1-C_4) alkyl, heterocycle, or substituted heterocycle;

R^4 represents hydrogen, halo, amino, nitro, (C_1-C_4) alkyl, (C_1-C_4) alkoxy, NHSO_2R^7 , NHCOR^8 , or COR^9 ;

R^5 represents hydrogen or halo;

- 20 R^6 represents hydrogen or (C_1-C_4) alkyl;

R^7 represents (C_1-C_4) alkyl, aryl, NH (C_1-C_4) alkylamine, or N,N- (C_1-C_4) dialkylamine;

R^8 represents (C_1-C_4) alkyl, (C_1-C_4) alkoxy, or aryl (C_1-C_4) alkoxy;

R^9 represents (C_1-C_4) alkyl or (C_1-C_4) alkoxy, and

- 25 R^{10} represents hydrogen, (C_1-C_4) alkyl, (C_3-C_7) cycloalkyl, or (C_1-C_4) alkyl- (C_3-C_7) cycloalkyl,

or a pharmaceutically acceptable salt thereof.

-82-

2. The compound according to Claim 1 wherein X represents $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{O}-$, or $-\text{CH}_2\text{S}-$.
3. The compound according to Claim 2 wherein X represents $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, or $-\text{CH}_2\text{O}-$.
4. The compound according to Claim 3 wherein X represents $-\text{CH}_2-$ or $-\text{CH}_2\text{CH}_2-$.
5. The compound according to Claim 3 wherein X represents $-\text{CH}_2\text{O}-$.
6. The compound according to any one of Claims 1-5 wherein R^1 represents hydrogen, $(\text{C}_1-\text{C}_4)\text{alkyl}$, $(\text{C}_3-\text{C}_7)\text{cycloalkyl}$, hydroxy $(\text{C}_1-\text{C}_4)\text{alkyl}$, halo $(\text{C}_1-\text{C}_4)\text{alkyl}$, $(\text{C}_1-\text{C}_4)\text{alkyl-heterocycle}$, $(\text{C}_1-\text{C}_4)\text{alkyl-NH}(\text{C}_1-\text{C}_4)\text{alkylamine}$, or $(\text{C}_1-\text{C}_4)\text{alkyl-N,N}-(\text{C}_1-\text{C}_4)\text{dialkylamine}$.
7. The compound according to Claim 6 wherein R^1 represents hydrogen, methyl, ethyl, propyl, isopropyl, $(\text{C}_3-\text{C}_7)\text{cycloalkyl}$, hydroxy $(\text{C}_1-\text{C}_4)\text{alkyl}$, halo $(\text{C}_1-\text{C}_4)\text{alkyl}$, $(\text{C}_1-\text{C}_4)\text{alkyl-heterocycle}$, $(\text{C}_1-\text{C}_4)\text{alkyl-NH}(\text{C}_1-\text{C}_4)\text{alkylamine}$, or $(\text{C}_1-\text{C}_4)\text{alkyl-N,N}-(\text{C}_1-\text{C}_4)\text{dialkylamine}$.
8. The compound according to Claim 7 wherein R^1 represents methyl, ethyl, propyl, isopropyl, $(\text{C}_3-\text{C}_7)\text{cycloalkyl}$, hydroxy $(\text{C}_1-\text{C}_4)\text{alkyl}$, halo $(\text{C}_1-\text{C}_4)\text{alkyl}$, $(\text{C}_1-\text{C}_4)\text{alkyl-heterocycle}$, $(\text{C}_1-\text{C}_4)\text{alkyl-NH}(\text{C}_1-\text{C}_4)\text{alkylamine}$, or $(\text{C}_1-\text{C}_4)\text{alkyl-N,N}-(\text{C}_1-\text{C}_4)\text{dialkylamine}$.
9. The compound according to any one of Claims 1-8 wherein R^2 represents hydrogen, halo, methyl, ethyl, propyl, isopropyl, heterocycle, or substituted heterocycle.
10. The compound according to Claim 9 wherein R^2 represents hydrogen, fluoro, chloro, bromo, methyl, ethyl, propyl, or isopropyl.

11. The compound according to any one of Claims 1-10 wherein R³ represents hydrogen, fluoro, chloro, or bromo.

12. The compound according to Claim 11 wherein R³ represents hydrogen or
5 fluoro.

13. The compound according to any one of Claims 1-12 wherein R⁴ represents hydrogen, halo, amino, nitro, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, NHSO₂R⁷, NHCOR⁸ wherein R⁸ represents (C₁-C₄)alkyl or (C₁-C₄)alkoxy, or COR⁹ wherein R⁹ represents
10 (C₁-C₄)alkyl or (C₁-C₄)alkoxy.

14. The compound according to Claim 13 wherein R⁴ represents hydrogen, halo, amino, nitro, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, or NH SO₂R⁷.

15. The compound according to Claim 14 wherein R⁴ represents hydrogen, halo, amino, nitro, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, or NH SO₂R⁷ wherein R⁷ represents (C₁-C₄)alkyl, aryl, or N,N-(C₁-C₄)dialkylamine.

16. The compound according to any one of Claims 1-15 wherein R⁵ represents
20 hydrogen, chloro, or fluoro.

17. The compound according to Claim 16 wherein R⁵ represents hydrogen.

18. The compound according to any one of Claims 1-17 wherein R⁶ represents
25 hydrogen, methyl, or ethyl.

19. A pharmaceutical composition comprising the compound according to any one of Claims 1-18 in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

30

20. A method of treating a disorder selected from the group consisting of Conn's Syndrome, primary and secondary hyperaldosteronism, increased sodium

retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction, atherosclerosis, Bartter's Syndrome, disorders associated with excess catecholamine levels, diastolic and systolic congestive heart failure

5 (CHF), peripheral vascular disease, diabetic nephropathy, cirrhosis with edema and ascites, esophageal varices, Addison's Disease, muscle weakness, increased melanin pigmentation of the skin, weight loss, hypotension, hypoglycemia, Cushing's Syndrome, obesity, hypertension, glucose intolerance, hyperglycemia, diabetes mellitus, osteoporosis, polyuria, polydipsia, inflammation, autoimmune disorders, tissue rejection associated

10 with organ transplant, malignancies such as leukemias and lymphomas, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia, modulation of the Th1/Th2 cytokine balance, chronic kidney disease, stroke and spinal

15 cord injury, hypercalcemia, hyperglycemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, and Little's syndrome, systemic inflammation, inflammatory bowel disease, systemic lupus erythematosus, discoid lupus erythematosus, polyarthritis nodosa, Wegener's granulomatosis, giant cell arthritis, rheumatoid arthritis,

20 osteoarthritis, hay fever, allergic rhinitis, contact dermatitis, atopic dermatitis, exfoliative dermatitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis, bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, hepatitis, cirrhosis, inflammatory scalp alopecia, panniculitis, psoriasis, inflamed cysts, pyoderma gangrenosum, pemphigus vulgaris, bullous pemphigoid,

25 dermatomyositis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type 1 reactive leprosy, capillary hemangiomas, lichen planus, erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema, multiform, cutaneous T-cell lymphoma, psychoses, cognitive disorders, memory disturbances, mood disorders, depression, bipolar disorder, anxiety disorders, and

30 personality disorders, comprising administering to a patient in need thereof a compound as claimed in any one of Claims 1-18, or a pharmaceutically acceptable salt thereof.

21. The method according to Claim 20 wherein the disorder is selected from the group consisting of diastolic or systolic congestive heart failure, inflammation, rheumatoid arthritis, hypertension, asthma, or chronic obstructive pulmonary disease.

22. The method according to Claim 21 wherein the disorder is diastolic or
5 systolic congestive heart failure, inflammation, hypertension, or rheumatoid arthritis.

23. The method according to Claim 20 wherein the disorder is atherosclerosis.

24. The use of a compound according to any one of Claims 1-18, or a
pharmaceutically acceptable salt thereof, as an agent for the treatment of Conn's
10 Syndrome, primary and secondary hyperaldosteronism, increased sodium retention,
increased magnesium and potassium excretion (diuresis), increased water retention,
hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial
fibrosis, myocardial infarction, atherosclerosis Bartter's Syndrome, disorders associated
with excess catecholamine levels, diastolic and systolic congestive heart failure (CHF),
15 peripheral vascular disease, diabetic nephropathy, cirrhosis with edema and ascites,
esophageal varices, Addison's Disease, muscle weakness, increased melanin
pigmentation of the skin, weight loss, hypotension, hypoglycemia, Cushing's Syndrome,
obesity, hypertension, glucose intolerance, hyperglycemia, diabetes mellitus, osteoporosis,
polyuria, polydipsia, inflammation, autoimmune disorders, tissue rejection associated
20 with organ transplant, malignancies such as leukemias and lymphomas, acute adrenal
insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa,
granulomatous polyarteritis, inhibition of myeloid cell lines, immune
proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia,
modulation of the Th1/Th2 cytokine balance, chronic kidney disease, stroke and spinal
25 cord injury, hypercalcemia, hyperglycemia, acute adrenal insufficiency, chronic primary
adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia,
cerebral edema, thrombocytopenia, and Little's syndrome, systemic inflammation,
inflammatory bowel disease, systemic lupus erythematosus, discoid lupus erythematosus,
polyarthritis nodosa, Wegener's granulomatosis, giant cell arthritis, rheumatoid arthritis,
30 osteoarthritis, hay fever, allergic rhinitis, contact dermatitis, atopic dermatitis, exfoliative
dermatitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease,
asthma, tendonitis, bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active

hepatitis, hepatitis, cirrhosis, inflammatory scalp alopecia, panniculitis, psoriasis, inflamed cysts, pyoderma gangrenosum, pemphigus vulgaris, bullous pemphigoid, dermatomyositis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type 1 reactive leprosy, capillary hemangiomas, lichen
5 planus, erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema, multiform, cutaneous T-cell lymphoma, psychoses, cognitive disorders, memory disturbances, mood disorders, depression, bipolar disorder, anxiety disorders, or personality disorder.

10 25. The use of a compound according to any one of Claims 1-18 for the manufacture of a medicament for the treatment of Conn's Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction,
15 atherosclerosis, Bartter's Syndrome, disorders associated with excess catecholamine levels, diastolic and systolic congestive heart failure (CHF), peripheral vascular disease, diabetic nephropathy, cirrhosis with edema and ascites, esophageal varices, Addison's Disease, muscle weakness, increased melanin pigmentation of the skin, weight loss, hypotension, hypoglycemia, Cushing's Syndrome, obesity, hypertension, glucose
20 intolerance, hyperglycemia, diabetes mellitus, osteoporosis, polyuria, polydipsia, inflammation, autoimmune disorders, tissue rejection associated with organ transplant, malignancies such as leukemias and lymphomas, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression
25 and regulation, hypercortisolemia, modulation of the Th1/Th2 cytokine balance, chronic kidney disease, stroke and spinal cord injury, hypercalcemia, hyperglycemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, and Little's syndrome, systemic inflammation, inflammatory bowel disease, systemic lupus
30 erythematosus, discoid lupus erythematosus, polyarthritis nodosa, Wegener's granulomatosis, giant cell arthritis, rheumatoid arthritis, osteoarthritis, hay fever, allergic rhinitis, contact dermatitis, atopic dermatitis, exfoliative dermatitis, urticaria,

-87-

angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis, bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, hepatitis, cirrhosis, inflammatory scalp alopecia, panniculitis, psoriasis, inflamed cysts, pyoderma gangrenosum, pemphigus vulgaris, bullous pemphigoid, dermatomyositis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type 1 reactive leprosy, capillary hemangiomas, lichen planus, erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema, multiform, cutaneous T-cell lymphoma, psychoses, cognitive disorders, memory disturbances, mood disorders, depression, bipolar disorder, anxiety disorders; or personality disorder.

10